Adoptive immunotherapy of lung cancer with immobilized anti- TCRγδ antibody-expanded human γδ T cells in peripheral blood

Cancer Biology and Therapy

Volumn 8, Issue 16, 2009, Pages 1540-1549

  Kang, Ning ^a   Zhou, Jianhua ^a   Zhang, Tie ^a   Wang, Lifang ^a   Lu, Fang ^b   Cui, Ying ^a   Cui, Lianxian ^a   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Adoptive immunotherapy; Ex vivo cell expansion; Gamma delta T cells; Lung cancer; Preclinical study; TCR ligandation; Tumor treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CD27 ANTIGEN; CD45RA ANTIGEN; CISPLATIN; FAS LIGAND; GAMMA INTERFERON; GRANZYME A; GRANZYME B; PAMIDRONIC ACID; PERFORIN; T LYMPHOCYTE RECEPTOR GAMMA DELTA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SOLID TUMOR; T GAMMA SIGMA LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG SCREENING; GENETICS; IMMUNOLOGY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; NUDE MOUSE; PROGNOSIS; TUMOR CELL LINE;

ADULT; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349127747     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.16.8950     Document Type: Article

References (41)

1. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002; 57:20-28 (Pubitemid 34081539)
2. Prasad US, Naylor AR, Walker WS, Lamb D, Cameron EW, Walbaum PR. Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 1989; 44:784-787 (Pubitemid 19255907)
3. Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC, et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 1997; 72:901-912 (Pubitemid 27459423)
4. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24:363-373 (Pubitemid 32825868)
5. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-854 (Pubitemid 35231542)
6. + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24:5060-5069
7. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-129
8. Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009; 113:1651-1660
9. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50.
10. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-393
11. Schultze JL, Nadler LM. T cell mediated immunotherapy for B cell lymphoma. J Mol Med 1999; 77:322-331
12. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25:243-265
13. Hayday AC. γδ cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975-1026.
14. Zhao J, Huang J, Chen H, Cui L, He W. Vdelta1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun 2006; 339:232-240 (Pubitemid 41697540)
15. Li J, Cui L, He W. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA. Cell Mol Immunol 2005; 2:253-258
16. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C, et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 2005; 65:7502-7508 (Pubitemid 41161286)
17. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007; 67:5-8. (Pubitemid 46142752)
18. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102:200-206 (Pubitemid 36759655)
19. Otto M, Barfield RC, Martin WJ, Iyengar R, Leung W, Leimig T, et al. Combination Immunotherapy with Clinical-Scale Enriched Human γδ T cells, hu14.18 Antibody, and the Immunocytokine Fc-IL7 in Disseminated Neuroblastoma. Clin Cancer Res 2005; 11:8486-8491
20. Bennouna J, Medioni J, Rolland F, Misset JL, Campone M, Sicard H, et al. Phase I clinical trial of BromoHydrin PyroPhosphate, BrHPP (Phosphostim), a Vγ9Vδ2 T lymphocytes agonist in combination with low dose Interleukin-2 in patients with solid tumors, J Clin Oncol (Meeting Abstracts) 2005; 23:2536.
21. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting Human γδT Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. Cancer Res 2007; 67:7450-7457 (Pubitemid 47206575)
22. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56:469-476 (Pubitemid 46204533)
23. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, et al. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58:493-502.
24. Yu S, He W, Chen J, Zhang F, Ba D. Expansion and immunological study of human tumor infiltrating gamma/delta T lymphocytes in vitro. Int Arch Allergy Immunol 1999; 119:31-37 (Pubitemid 29204580)
25. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003; 31:154.
26. Wang Z, Zhang T, Hu H, Zhang H, Yang Z, Cui L, et al. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett 2008; 272:242-252
27. Kabelitz D, Wesch D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 2007; 66:320-328 (Pubitemid 47063194)
28. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, et al. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol 2008; 180:3578-3584
29. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-392 (Pubitemid 30463353)
30. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 2001; 166:5508-5514 (Pubitemid 32374172)
31. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. Immunol 2005; 174:1338-1347
32. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23:14-18 (Pubitemid 34098956)
33. + lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183:1681-1696
34. Ebert LM, Meuter S, Moser B. Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J Immunol 2006; 176:4331-4336 (Pubitemid 44264412)
35. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol 2001; 125:256-263 (Pubitemid 32722298)
36. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003; 198:391-397 (Pubitemid 36980610)
37. Chien YH, Konigshofer Y. Antigen recognition by gammadelta T cells. Immunol Rev 2007; 215:46-58.
38. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357
39. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-5239
40. Van Kroonenburgh MJ, Pauwels EK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 1988; 9:919-930
41. Hasholzner U, Stieber P, Meier W, Lamerz R. Value of HAMA - determination in clinical practice - an overview. Anticancer Res 1997; 17:3055-3058 (Pubitemid 27434856)